FGEN FibroGen Inc
4,426
$1.17
$0.05
(4.10%)
| Watchers | 4,426 |
| 52-Wk Low | $0.3333 |
| 52-Wk High | $19.47 |
| Market Cap | $121.36M |
| Volume | 302,456.00 |
| 52-Wk High | $19.47 |
| 52-Wk Low | $0.3333 |
FibroGen Shares Climb On Strong Q1 SalesBenzinga • 3 days ago
FibroGen reported quarterly losses of 33 cents per share which missed the analyst consensus estimate of $(0.31) and represents a 59.26% increase year-over-year. Quarterly sales clocked in at $55.902...
Share to Feed
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in FibroGen Inc (FGEN), where a total volume of 13,026 contracts has been traded...
Investors eyeing a purchase of FibroGen Inc (FGEN) stock, but tentative about paying the going market price of 1.30/share, might benefit from considering selling puts among the alternative...
FibroGen reveals Phase 1 results for FG-3246 for metastatic castration-resistant prostate cancer. Promising efficacy metrics and plans for enhanced therapeutic strategies signal potential...
FibroGen, Acorda Therapeutics, Enveric Biosciences among healthcare movers...
FG-3246 demonstrated efficacy in adenocarcinoma selected cohorts receiving biologically active doses of FG-3246 at 1.2 mg/kg in heavily pre-treated, biomarker unselected patients: Median...
Apogee Therapeutics Inc. APGE, a clinical-stage company, is focused on developing novel therapies for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease...
SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology...